Related Experiment Video
Updated: Mar 27, 2026
Purification of Platelets from Mouse Blood
Published on: May 7, 2019
[Classification therapy in 405 children with immune thrombocytopenia]
Na Zhang1, Hui Jiang1, Jingbo Shao1
1Department of Hematology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200040, China.
Insights
Classification treatment for childhood immune thrombocytopenia (ITP) is effective and safe. This approach helps avoid overtreatment and reduces drug side effects, improving children's quality of life.
Area of Science:
- Pediatric Hematology
- Immunology
- Clinical Therapeutics
Background:
- Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder.
- Effective treatment strategies are crucial for managing ITP in children.
- Classification-based treatment aims to optimize outcomes and minimize risks.
Purpose of the Study:
- To evaluate the efficacy and safety of a classification-based treatment approach for childhood ITP.
- To determine if specific platelet counts and bleeding status can guide treatment decisions.
- To assess the impact of this strategy on long-term outcomes and quality of life.
Main Methods:
- A cohort of 405 newly diagnosed pediatric ITP patients was studied.
- Patients were classified into observation or therapy groups based on platelet count (<20×10⁹/L) and bleeding status.
- Follow-up duration was a median of 20-22 months for both groups.
Main Results:
- The therapy group achieved an 80.44% curative rate in the acute phase.
- In the observation group, 82.22% achieved complete response (CR) or response (R) criteria.
- Overall effectiveness exceeded 87% within one year, with no severe adverse events or deaths reported.
Conclusions:
- Utilizing platelet count <20×10⁹/L and/or active bleeding as criteria for classification therapy is reasonable.
- This approach allows nearly half of patients to avoid overtreatment, reducing drug side effects.
- Classification treatment improves quality of life for children with ITP.
Objective:
To explore the efficiency and safety of immune thrombocytopenia（ITP）in children through classification treatment.
Methods:
405 newly diagnosed ITP patients were enrolled in this study from January 1st 2013 to August 31st 2014. The cases were divided into observation group and therapy group according to the initial platelet count of less than 20×10⁹/L or the cases of active bleeding. There were 104 male cases and 76 female cases in observation group with the media platelet count of 46 （20-89）×10⁹/L. They were followed up with a median of 20 months. The therapy group，including 131 males and 94 females with a median platelet count of 11（1-19）×10⁹/L, were followed up by 22 months.
Results:
The total curative rate at acute period was 80.44%（181/225）in therapy group with the first line treatment. In observation group, 148 cases（82.22%）reached complete response（CR）or response（R） criteria. 44 patients came into persistent period with an effective rate of 34.09%（15/44）in therapy group. The overall effectiveness over one year was 87.11%（196/255）. In observation group, 32 cases came into persistent period and 13 cases（40.63%）got the CR or R line. After one year of observation, 161 cases （89.44%）reached the CR or R standard. In therapy group, 5 out of 29 patients（17.24%）in chronic period got CR or R. While in observation group, 6 out of 19 cases（31.58%）reached the CR or R standard. The elder children over 10 years had risk factors in response in two groups. There was no severe bleeding or adverse effect or dead cases in this study.
Conclusion:
It is reasonable to take platelet count <20×10⁹/L and（or）active bleeding as the dividing line for classification therapy indications. Nearly half of the cases could avoid over therapy and decreased the risk of drugs side effect to improve life quality.
